https://mindmedicinelaw.com/briefing/new-ptsd-memory-model-implications-for-therapy-trials-20260507-826Psychedelic Research Journalen2026-05-07T15:04:52.707881+00:00New PTSD Memory Model: Implications for Therapy & TrialsPTSD memory dynamics, MDMA-assisted therapy, clinical trials, pathological crystallization, exposure therapy, non-Markovian signature, neurobiological parameters, therapeutic mechanisms, Schrödinger–REK–RGB modelhttps://mindmedicinelaw.com/briefing/mdma-for-autism-pilot-insights-on-social-anxiety-20260506-827Psychedelic Research Journalen2026-05-07T15:05:04.929150+00:00MDMA for Autism: Pilot Insights on Social Anxietymdma-assisted therapy, autism spectrum disorder, social anxiety, clinical trials, prosocial behavior, oxytocin release, neuroimaging studies, adverse events, cardiovascular risks, gender differenceshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-executive-order-progress-barriers-20260505-921Psychedelic Research Journalen2026-05-07T15:05:15.521764+00:00Psychedelic Therapy Executive Order: Progress & Barrierspsychedelic therapy, executive order, mental health, access barriers, psilocybin, MDMA, clinical trials, federal policy, neuroplasticity, mental health treatmenthttps://mindmedicinelaw.com/briefing/fda-nears-approval-of-psychedelics-texas-advocates-lead-20260505-648Psychedelic Research Journalen2026-05-06T15:05:05.904700+00:00FDA Nears Approval of Psychedelics; Texas Advocates LeadFDA approval, psychedelic treatments, Texas advocacy, mental health, clinical trials, psilocybin, MDMA, state-level support, patient access, therapeutic usehttps://mindmedicinelaw.com/briefing/dea-lists-hexahydrocannabinol-as-schedule-i-substance-20260504-362Psychedelic Research Journalen2026-05-05T22:44:51.430946+00:00DEA Lists Hexahydrocannabinol as Schedule I SubstanceDEA, hexahydrocannabinol, Schedule I, Controlled Substances Act, cannabinoids, psychedelic research, drug policy, HHC regulation, legal compliance, public healthhttps://mindmedicinelaw.com/briefing/fda-s-rolling-review-of-comp360-psilocybin-therapy-20260504-484Psychedelic Research Journalen2026-05-05T22:44:40.800354+00:00FDA's Rolling Review of COMP360 Psilocybin TherapyFDA rolling review, COMP360 psilocybin therapy, COMPASS Pathways, depression treatment, psychedelic research, drug approval process, mental health, regulatory strategy, clinical trials, market impacthttps://mindmedicinelaw.com/briefing/federal-marijuana-rescheduling-implications-for-psychedelics-20260502-652Psychedelic Research Journalen2026-05-06T15:05:19.244956+00:00Federal Marijuana Rescheduling: Implications for Psychedelicsfederal rescheduling, marijuana policy, psychedelic research, drug policy shift, controlled substances act, legal risks, market dynamics, therapeutic benefits, regulatory landscape, research barriershttps://mindmedicinelaw.com/briefing/esketamine-enhances-recovery-in-elderly-knee-surgery-20260501-859Psychedelic Research Journalen2026-05-07T15:05:39.169000+00:00Esketamine Enhances Recovery in Elderly Knee Surgeryesketamine, elderly patients, knee arthroplasty, postoperative recovery, anesthetic practices, pain management, QoR-40 score, clinical trials, surgical outcomeshttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-enhancing-postoperative-sleep-quality-20260501-861Psychedelic Research Journalen2026-05-07T15:05:27.103314+00:00Esketamine's Role in Enhancing Postoperative Sleep Qualityesketamine, postoperative sleep quality, systematic review, meta-analysis, surgical recovery, clinical guidelineshttps://mindmedicinelaw.com/briefing/fda-fast-tracks-psychedelics-for-mental-health-treatment-20260501-920Psychedelic Research Journalen2026-05-07T15:04:40.008215+00:00FDA Fast-Tracks Psychedelics for Mental Health TreatmentFDA, psychedelic drugs, mental health treatment, fast-track designation, clinical trials, psilocybin, MDMA, drug policy, therapeutic potential, regulatory shifthttps://mindmedicinelaw.com/briefing/psychological-support-in-psilocybin-therapy-a-key-component-20260501-700Psychedelic Research Journalen2026-05-06T22:03:40.412042+00:00Psychological Support in Psilocybin Therapy: A Key Componentpsilocybin therapy, psychological support, depression treatment, serotonin receptors, clinical trials, mental health, pharmacology, neuroplasticity, treatment protocols, holistic approachhttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-trd-in-older-adults-efficacy-and-tolerability-20260501-414Psychedelic Research Journalen2026-05-06T15:06:02.801904+00:00Ketamine and Esketamine for TRD in Older Adults: Efficacy and Tolerabilityketamine, esketamine, treatment-resistant depression, older adults, geriatric psychiatry, systematic review, meta-analysis, adverse effects, clinical trials, antidepressant efficacyhttps://mindmedicinelaw.com/briefing/ketamine-s-efficacy-in-older-adults-with-trd-analyzed-20260501-416Psychedelic Research Journalen2026-05-06T15:05:49.480860+00:00Ketamine's Efficacy in Older Adults with TRD Analyzedketamine, esketamine, treatment-resistant depression, older adults, systematic review, meta-analysis, geriatric psychiatry, clinical guidelines, adverse events, long-term outcomeshttps://mindmedicinelaw.com/briefing/esketamine-s-clinical-progress-global-regulatory-and-safety-insights-20260501-415Psychedelic Research Journalen2026-05-06T15:05:32.680260+00:00Esketamine's Clinical Progress: Global Regulatory and Safety Insightsesketamine, treatment-resistant depression, rapid-acting antidepressant, NMDA receptor, regulatory approval, dissociative symptoms, cognitive impairment, long-term safety, neuroplasticity, glutamatergic signalinghttps://mindmedicinelaw.com/briefing/dea-schedules-synthetic-cannabinoids-as-schedule-i-substances-20260501-368Psychedelic Research Journalen2026-05-05T22:44:29.527091+00:00DEA Schedules Synthetic Cannabinoids as Schedule I SubstancesDEA, synthetic cannabinoids, Schedule I, controlled substances, research regulation, public health, policy implications, regulatory burdens, drug enforcement, substance abusehttps://mindmedicinelaw.com/briefing/ketamine-vs-ect-cognitive-benefits-in-trd-patients-20260430-419Psychedelic Research Journalen2026-05-06T22:04:05.974149+00:00Ketamine vs. ECT: Cognitive Benefits in TRD Patientsketamine, electroconvulsive therapy, treatment-resistant depression, cognitive function, clinical trials, mental health treatmenthttps://mindmedicinelaw.com/briefing/ketamine-vs-ssris-efficacy-in-treatment-resistant-depression-20260430-420Psychedelic Research Journalen2026-05-06T22:03:55.643037+00:00Ketamine vs SSRIs: Efficacy in Treatment-Resistant Depressionketamine, SSRIs, treatment-resistant depression, rapid-acting therapies, clinical trials, mental health, antidepressants, patient outcomes, psychiatric treatments, depression researchhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treating-resistant-depression-explored-20260430-417Psychedelic Research Journalen2026-05-06T15:06:16.256365+00:00Ketamine's Role in Treating Resistant Depression Exploredketamine, treatment-resistant depression, anti-suicidal efficacy, depressive symptoms, Maudsley Staging Method, clinical trials, mental health, psychiatric treatment, personalized medicine, neurosciencehttps://mindmedicinelaw.com/briefing/mdma-therapy-for-ptsd-us-military-s-2027-initiative-20260430-488Psychedelic Research Journalen2026-05-05T22:43:59.179061+00:00MDMA Therapy for PTSD: US Military's 2027 InitiativeMDMA therapy, PTSD treatment, US military, psychedelic research, mental health, clinical trials, policy implications, regulatory approval, psychedelic therapies, military mental healthhttps://mindmedicinelaw.com/briefing/comparative-study-of-2c-b-mdma-and-psilocybin-effects-20260428-468Psychedelic Research Journalen2026-05-06T22:04:25.312066+00:00Comparative Study of 2C-B, MDMA, and Psilocybin Effects2C-B, MDMA, psilocybin, psychedelic research, clinical trials, dose-dependent effects, regulatory policy, therapeutic protocols, public health, safety profileshttps://mindmedicinelaw.com/briefing/neural-changes-in-depression-via-ketamine-implications-20260428-472Psychedelic Research Journalen2026-05-06T22:04:15.789410+00:00Neural Changes in Depression via Ketamine: Implicationsketamine, treatment-resistant depression, fMRI, PET, neural changes, mental health treatment, clinical guidelines, neuroscience, therapeutic strategies, brain imaginghttps://mindmedicinelaw.com/briefing/psychedelics-executive-order-shifts-u-s-policy-focus-20260428-485Psychedelic Research Journalen2026-05-05T22:44:17.909817+00:00Psychedelics: Executive Order Shifts U.S. Policy Focuspsychedelics, executive order, Schedule I, treatment priority, clinical trials, mental health, drug policy reform, therapeutic use, research funding, regulatory frameworkhttps://mindmedicinelaw.com/briefing/fda-reschedules-marijuana-to-schedule-iii-policy-shift-20260428-335Psychedelic Research Journalen2026-05-05T22:44:08.374727+00:00FDA Reschedules Marijuana to Schedule III: Policy ShiftFDA rescheduling, Schedule III marijuana, Controlled Substances Act, medical marijuana policy, marijuana research, federal drug policy, state medical marijuana, marijuana regulation, THC products, international drug treatieshttps://mindmedicinelaw.com/briefing/eeg-biomarker-predicts-ketamine-response-in-depression-20260427-430Psychedelic Research Journalen2026-05-06T22:04:36.028458+00:00EEG Biomarker Predicts Ketamine Response in DepressionEEG biomarker, ketamine response, treatment-resistant depression, thalamic filter model, thalamic reticular nucleus, personalized treatment, antidepressant response, neuroscience, clinical trials, mental health